top of page
.png)
InformAI News
InformAI Receives FDA 510(k) Clearance for RadOncAI Radiation Therapy Dose Planning Software
AI-powered SaMD streamlines radiation therapy dose planning for head & neck cancers HOUSTON, TX, UNITED STATES, July 15, 2026 /EINPresswire.com/ InformAI, Inc., a leader in innovative medical technology, is proud to announce that it has received 510(k) approval from the U.S. Food and Drug Administration (FDA) to market an AI-enabled radiation therapy dose planning software, RadOncAI™. This clinician co-pilot software-as-a-medical-device uses artificial intelligence (AI) to o
Jun 18
Head & Neck Cancer: Dose Prediction with Deep Learning
Pettit RW, Marlatt B. Head & Neck Cancer: Dose Prediction with Deep Learning. NVIDIA GTC Conference, 2023.
Mar 31, 2023
InformAI Presents At 2023 Nvidia GTC
InformAI was competitively selected as part of the Nvidia Inception Program to present Head & Neck Cancer: Dose Prediction with Deep...
Mar 29, 2023
InformAI Wins $1.5M Cancer Prevention & Research Initiative (CPRIT) Grant
InformAI is pleased to announce that we are the recipient of a $1.55M award from the Cancer Prevention and Research Institute of Texas...
Nov 15, 2022
InformAI Joins UTSW as Entrepreneur In Residence
InformAI has been invited by University of Texas Southwestern Medical Center (UTSW) to join its Entrepreneur In Residence (EIR) program...
Sep 14, 2022
bottom of page